氧氟沙星和左氧氟沙星用于预防和治疗儿童耐多药结核病的药代动力学
Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.
作者信息
Thee S, Garcia-Prats A J, McIlleron H M, Wiesner L, Castel S, Norman J, Draper H R, van der Merwe P L, Hesseling A C, Schaaf H S
机构信息
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
出版信息
Antimicrob Agents Chemother. 2014 May;58(5):2948-51. doi: 10.1128/AAC.02755-13. Epub 2014 Feb 18.
Abstract
Limited data on fluoroquinolone pharmacokinetics and cardiac effects in children exist. Among 22 children receiving drug-resistant tuberculosis prophylaxis or treatment, serum concentrations following oral doses of levofloxacin (15 mg/kg of body weight) and ofloxacin (20 mg/kg) were lower than those expected from existing pediatric data, possibly due to differences in the formulations (crushed tablets). Drug exposures were lower than those in adults following standard doses and below the proposed pharmacodynamic targets, likely due to more rapid elimination in children. No QT prolongation was observed.
摘要
关于儿童氟喹诺酮类药物的药代动力学和心脏效应的数据有限。在22名接受耐多药结核病预防或治疗的儿童中，口服左氧氟沙星（15毫克/千克体重）和氧氟沙星（20毫克/千克）后的血清浓度低于现有儿科数据预期的值，这可能是由于制剂（压碎的片剂）不同所致。标准剂量后儿童的药物暴露量低于成人，且低于提议的药效学靶点，这可能是因为儿童的药物消除更快。未观察到QT间期延长。
相似文献
1
Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.氧氟沙星和左氧氟沙星用于预防和治疗儿童耐多药结核病的药代动力学
Antimicrob Agents Chemother. 2014 May;58(5):2948-51. doi: 10.1128/AAC.02755-13. Epub 2014 Feb 18.
2
Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.南非儿童耐多药结核病治疗中的左氧氟沙星群体药代动力学。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01521-17. Print 2018 Feb.
3
Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis.氧氟沙星在耐药性肺结核儿童中的药代动力学及安全性
Antimicrob Agents Chemother. 2015 Oct;59(10):6073-9. doi: 10.1128/AAC.01404-15. Epub 2015 Jul 20.
4
Fluoroquinolones for the treatment of tuberculosis in children.氟喹诺酮类药物治疗儿童结核病。
Tuberculosis (Edinb). 2015 May;95(3):229-45. doi: 10.1016/j.tube.2015.02.037. Epub 2015 Feb 14.
5
Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.新型儿童左氧氟沙星分散片在耐多药结核病暴露儿童中的药代动力学、安全性和剂量研究。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01865-18. Print 2019 Apr.
6
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.治疗耐多药结核病患者的血浆药物活性。
Antimicrob Agents Chemother. 2014;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18.
7
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.南非儿童中左氧氟沙星不敏感肺炎链球菌的出现及耐多药结核病的治疗：一项队列观察性监测研究
Lancet. 2008 Mar 29;371(9618):1108-13. doi: 10.1016/S0140-6736(08)60350-5. Epub 2008 Mar 21.
8
Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.左氧氟沙星在耐多药结核病患者中的空洞穿透情况。
Antimicrob Agents Chemother. 2015;59(6):3149-55. doi: 10.1128/AAC.00379-15. Epub 2015 Mar 16.
9
Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.儿童耐多药结核病治疗中左氧氟沙星长期应用的临床与心脏安全性。
Clin Infect Dis. 2018 Nov 13;67(11):1777-1780. doi: 10.1093/cid/ciy416.
10
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.氟喹诺酮类药物在耐药结核病中的应用：培养转换和药代动力学/药效学目标达标指导剂量选择。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00279-19. Print 2019 Jul.
引用本文的文献
1
Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment.左氧氟沙星可分散片剂和非分散片剂在接受结核病预防性治疗儿童中的可接受性。
IJTLD Open. 2024 Feb 1;1(2):69-75. doi: 10.5588/ijtldopen.23.0462. eCollection 2024 Feb.
2
Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis of Second-Line Anti-Tubercular Drugs in Indian Children with Multi-Drug Resistance.印度多药耐药儿童二线抗结核药物的药代动力学-药效学（PK-PD）分析
Indian J Pediatr. 2024 May 28. doi: 10.1007/s12098-024-05135-9.
3
Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.抗结核药物耐药儿童左氧氟沙星的药代动力学和最佳剂量：一项个体患者数据分析荟萃分析。
Clin Infect Dis. 2024 Mar 20;78(3):756-764. doi: 10.1093/cid/ciae024.
4
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.抗逆转录病毒和抗结核药物在 HIV/TB 合并感染儿童中的药代动力学：系统评价。
J Antimicrob Chemother. 2020 Dec 1;75(12):3433-3457. doi: 10.1093/jac/dkaa328.
5
Real-world safety evaluation of musculoskeletal adverse events associated with Korean pediatric fluoroquinolone use: a nationwide longitudinal retrospective cohort study.韩国儿科氟喹诺酮类药物相关肌肉骨骼不良事件的真实世界安全性评价：一项全国性纵向回顾性队列研究。
Sci Rep. 2019 Dec 27;9(1):20156. doi: 10.1038/s41598-019-56815-y.
6
Pharmacological limitations of phage therapy.噬菌体疗法的药理学限制。
Ups J Med Sci. 2019 Nov;124(4):218-227. doi: 10.1080/03009734.2019.1688433. Epub 2019 Nov 14.
7
Pharmacokinetics of Second-Line Anti-Tubercular Drugs.二线抗结核药物的药代动力学。
Indian J Pediatr. 2019 Aug;86(8):714-716. doi: 10.1007/s12098-019-02923-6. Epub 2019 Mar 28.
8
Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.左氧氟沙星在耐药结核病暴露儿童治疗中的药代动力学。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02569-18. Print 2019 May.
9
Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.新型儿童左氧氟沙星分散片在耐多药结核病暴露儿童中的药代动力学、安全性和剂量研究。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01865-18. Print 2019 Apr.
10
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP).左氧氟沙星与安慰剂预防耐多药结核病儿童接触者结核病：一项III期整群随机对照试验（TB-CHAMP）的研究方案
Trials. 2018 Dec 20;19(1):693. doi: 10.1186/s13063-018-3070-0.
本文引用的文献
1
High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.儿童耐多药结核病治疗成功率高：一项观察性队列研究。
Thorax. 2014 May;69(5):458-64. doi: 10.1136/thoraxjnl-2013-203900. Epub 2013 Sep 24.
2
Understanding dosing: children are small adults, neonates are immature children.了解剂量：儿童是小大人，新生儿是不成熟的儿童。
Arch Dis Child. 2013 Sep;98(9):737-44. doi: 10.1136/archdischild-2013-303720. Epub 2013 Jul 5.
3
The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.南非开普敦儿童中耐药结核病的流行演变。
Int J Tuberc Lung Dis. 2012 Jul;16(7):928-33. doi: 10.5588/ijtld.11.0679. Epub 2012 May 8.
4
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.结核分枝杆菌临床分离株中 gyrA 突变与氧氟沙星和莫西沙星表型敏感性水平的关系。
J Antimicrob Chemother. 2012 May;67(5):1088-93. doi: 10.1093/jac/dks033. Epub 2012 Feb 22.
5
Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome.儿童确诊的耐多药结核病：临床特征、治疗和结局。
Clin Infect Dis. 2012 Jan 15;54(2):157-66. doi: 10.1093/cid/cir772. Epub 2011 Nov 3.
6
An LC-MS/MS method for the determination of ofloxacin in 20 μl human plasma.一种 LC-MS/MS 方法，用于测定 20μl 人血浆中的氧氟沙星。
J Pharm Biomed Anal. 2012 Jan 25;58:177-81. doi: 10.1016/j.jpba.2011.09.030. Epub 2011 Oct 1.
7
Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.氟喹诺酮类药物：治疗耐药结核病的基石：药代动力学和药效学方法。
Curr Pharm Des. 2011;17(27):2900-30. doi: 10.2174/138161211797470200.
8
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.左氧氟沙星、加替沙星和莫西沙星在成年肺结核患者中的群体药代动力学。
Antimicrob Agents Chemother. 2008 Mar;52(3):852-7. doi: 10.1128/AAC.01036-07. Epub 2007 Dec 10.
9
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.莫西沙星、氧氟沙星、司帕沙星和环丙沙星对结核分枝杆菌的作用：评估最能预测体内疗效的体外和药效学指标。
Antimicrob Agents Chemother. 2007 Feb;51(2):576-82. doi: 10.1128/AAC.00414-06. Epub 2006 Dec 4.
10
Zotero 插件